Prodotti competitors / Area Kite
FDA approves lisocabtagene maraleucel (Breyanzi) for relapsed or refractory mantle cell lymphoma (MCL) after two prior lines of therapy
![Immagine News](/media/l4el5htd/cat-2.jpg?anchor=center&mode=crop&width=722&height=442)
On May 30, 2024, the Food and Drug Administration (FDA) approved lisocabtagene maraleucel - Breyanzi for adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two prior lines of systemic therapy, including a Bruton tyrosine kinase inhibitor (BTKi).
Full prescribing information for Breyanzi will be posted here.
Grazie per il tuo feedback!